The prevalence of hepatitis B virus, human T‐lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa
Vox Sanguinis · 2024
DOI: 10.1111/vox.13735 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Reynier J Willemse und 6 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Medicine and Technical services, South African National Blood Service, Johannesburg, South Africa. Hauptthemen laut MEDLINE: Hepatitis B, HIV Infections. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FIC NIH HHS.
Abstract (Originalsprache)
Background and Objectives South Africa has a high prevalence of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and to a lesser extent human T‐lymphotropic virus (HTLV). Each of these agents is transfusion‐transmissible (TT) but deciding whether to implement preventive screening depends upon knowledge of background prevalence in transfused patients. We determined the prevalence of HIV, HBV and HTLV I/II among blood transfusion recipients in South African hospitals. Materials and Methods We obtained identity‐unlinked samples used for blood cross‐matching at 634 South African hospitals served by the South African National Blood Service (SANBS). The ABBOTT Alinity S® Immunochemiluminescent system measured HIV, HBV and HTLV I/II antibodies. Repeatedly reactive samples were confirmed using the Roche Cobas® 8000. Logistic regression was performed to investigate the determinants of associations for HIV, HBV and HTLV infections.
Results
The overall prevalences of HIV, HBV and HTLV were 37.8%, 7.4% and 0.6%, respectively. The HIV prevalence in blood recipients was twice as high as general population estimates. Public hospital patients had a significantly higher prevalence compared with private hospital patients for HIV and HBV. HIV prevalence was significantly higher in females, and HBV prevalence was significantly higher in males, excluding the unknown gender results.
Conclusion
Patients receiving blood transfusions in South Africa have high rates of HIV and HBV infection that should be taken into consideration when determining donor screening strategies for other viral infections. Measurable prevalence of HTLV indicates endemicity of this infection in South Africa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Transfusion Medicine and Technical services, South African National Blood Service, Johannesburg, South Africa.
- Faculty of Computer and Applied Sciences, Health Science Department, Vaal University of Technology (VUT), Vereeniging, South Africa.
- Departments of Laboratory Medicine and Epidemiology/Biostatistics, University of California San Francisco (UCSF), San Francisco, California, USA.
- Vitalant Research Institute, San Francisco, California, USA.
- Division of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
- School of Clinical Medicine, University of the Free State, Bloemfontein, South Africa.
ORCID-Profile: Reynier J Willemse, Marion Vermeulen
Förderung
- FIC NIH HHS
Zitieren
APA
Willemse, R. J., Grobler, C. J., Murphy, E. L., Roubinian, N., Colemen, C., Machaba, S., & Vermeulen, M. (2024). The prevalence of hepatitis B virus, human T‐lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa. Vox Sanguinis. https://doi.org/10.1111/vox.13735
Vancouver
Willemse RJ, Grobler CJ, Murphy EL, Roubinian N, Colemen C, Machaba S, et al. The prevalence of hepatitis B virus, human T‐lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa. Vox Sanguinis. 2024. doi:10.1111/vox.13735
BibTeX
@article{Willemse2024,
author = {Willemse, Reynier J and Grobler, Christa J and Murphy, Edward L and Roubinian, Nareg and Colemen, Charl and Machaba, Solly and Vermeulen, Marion},
title = {The prevalence of hepatitis B virus, human T‐lymphotropic virus and human immunodeficiency virus in patients receiving blood transfusions in South Africa},
journal = {Vox Sanguinis},
year = {2024},
doi = {10.1111/vox.13735}
}
EUVIMED